# A Study of BLB-201 RSV Vaccine in Infants and Children

> **NCT05655182** · PHASE1,PHASE2 · RECRUITING · sponsor: **Blue Lake Biotechnology Inc.** · enrollment: 137 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** PIV5-vectored RSV Vaccine (BLB-201) Low Dose
- **BIOLOGICAL:** PIV5-vectored RSV Vaccine (BLB-201) High Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05655182
- **Lead sponsor:** Blue Lake Biotechnology Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2028-07-30
- **Final completion:** 2028-07-30
- **Target enrollment:** 137 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05655182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05655182, "A Study of BLB-201 RSV Vaccine in Infants and Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05655182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*